Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT01466036Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2012
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in Pancreatic neuroendocrine tumor (PanNET), Carcinoid Tumor (CT), sponsored by Dana-Farber Cancer Institute. Started Jul 2012; status: completed.
02
Drugs
cabozantinib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT01466036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466036.